Australian Lucassin approval as US trial continues
This article was originally published in Scrip
Executive Summary
Australian regulators have approved Ikaria's Lucassin (terlipressin) for the treatment of hepatorenal syndrome type 1 (HRS 1) in patients who are actively being considered for a liver transplant, making it the first approved treatment for HRS 1, the company said.